Hindustan Unilever (HUL): For Q2 FY25, HUL’s total revenue increased by 1.93% year-on-year to ₹15,926 crore. However, its EBITDA dropped slightly by 0.1% to ₹3,793 crore, and the net profit fell by 2.33% to ₹2,595 crore. The EBITDA margin also shrank by 48 basis points to 23.81%. Despite the fall in profits, HUL met analysts’ expectations and announced an interim dividend of ₹29 per share. The company also decided to separate its ice cream business due to its smaller profitability contribution.
State Bank of India (SBI): India’s largest bank, SBI, raised ₹5,000 crore through Additional Tier-I (AT-I) bonds at a 7.98% interest rate. This was the bank’s first AT-I bond issuance in FY25, aimed at boosting its capital reserves. The bonds can be called after 10 years and comply with Basel-III rules.
Piramal Pharma: In Q2 FY25, Piramal Pharma reported a big jump in profits, with net profit up 350% year-on-year to ₹22.59 crore, compared to ₹5.02 crore in Q2 FY24. The company’s revenue also grew by 17.3% to ₹2,241.75 crore.
Sona BLW Precision Forgings: Sona BLW saw a 15.7% year-on-year rise in consolidated net profit, reaching ₹143.6 crore in Q2 FY25. The company’s revenue increased by 17.1% to ₹922.2 crore, while EBITDA grew by 14.7% to ₹252.3 crore. However, the EBITDA margin dropped slightly to 27.4% from 27.9% last year.
AU Small Finance Bank: AU Small Finance Bank reported a 42.2% year-on-year rise in net profit to ₹571.2 crore in Q2 FY25. Revenue increased by 58.1% to ₹1,974.4 crore. However, the bank’s asset quality worsened, with its gross NPA rising to 1.98% from 1.78%, and net NPA increasing to 0.75% from 0.63% quarter-on-quarter.
Dr Lal PathLabs: The diagnostics company posted an 18.2% year-on-year increase in consolidated net profit, reaching ₹131 crore in Q2 FY25. Revenue grew by 9.8% to ₹660 crore, while EBITDA rose by 13.9% to ₹202 crore. The EBITDA margin also improved by 110 basis points to 30.7%. Dr Lal PathLabs declared an interim dividend of ₹6 per share.
Pidilite Industries: Pidilite, the company behind Fevicol, reported a 17.8% increase in net profit for Q2 FY25, reaching ₹540.3 crore. Revenue growth was modest, reflecting the positive impact of lower input costs.
Thyrocare Technologies: Thyrocare’s consolidated net profit increased by 29% year-on-year to ₹26.4 crore in Q2 FY25. Revenue grew by 20% to ₹177.4 crore, and EBITDA surged by 28% to ₹48.2 crore. The EBITDA margin expanded by 200 basis points to 27%.
NLC India: NLC India has entered a joint venture with Rajasthan Rajya Vidyut Utpadan Nigam to build a lignite-based thermal power plant with a 3×125 MW capacity. NLC India’s subsidiary, NLC India Renewables, also signed another joint venture to develop 2,000 MW of renewable energy projects in Rajasthan.
Mankind Pharma: Mankind Pharma, together with its subsidiary Appian Properties, has completed the acquisition of a 100% stake in Bharat Serums and Vaccines for ₹13,768 crore, making Bharat Serums a wholly owned subsidiary.
Q2 Results Expected Today: Companies scheduled to announce their Q2 FY25 results today include ITC, IndusInd Bank, NTPC, ACC, JSW Energy, Colgate-Palmolive, Godrej Consumer Products, Aarti Drugs, Adani Total Gas, Adani Wilmar, and others.
Disclaimer: The views and investment tips expressed by investment experts on Sharepriceindia.com are their own and not those of the website or its management. Sharepriceindia.com advises users to check with certified experts before taking any investment decisions.
